Results for this period
Interim period (second quarter)1 April 2026–30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased due to growth in domestic and overseas sales of “Strong Wakamoto” and an increase in contract manufacturing of ophthalmic products in the global business, among other factors. Gross profit declined due to the impact of the drug price revision and other factors.
None ("There are no applicable matters.")
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥4,792 million (YoY +9.4%) |
| Operating profit | ¥-334 million |
| Ordinary income | ¥-303 million |
| Profit attributable to owners of the parent | ¥-181 million |
| Net income per share | -¥5.21 |
| Equity ratio | End of the current fiscal period 73.6 / End of previous period 72.8 |
| Total assets | ¥15,717 million |
| Net assets | ¥11,568 million |
| Cash flows from operating activities | ¥-490,092 thousand |
| Cash flows from investing activities | ¥-397,189 thousand |
| Cash flows from financing activities | ¥392,505 thousand |
| Cash and cash equivalents at end of period | ¥1,511,399 thousand |
| Full-year earnings forecast | Net Sales ¥11,000 million (YoY +11.0%) / Operating profit ¥200 million (YoY -21.7%) / Ordinary income ¥200 million (YoY -22.0%) / Net income ¥230 million (YoY +1.2%) |
| Annual Dividend Forecast | ¥3.5 → ¥3.5（0.0%） |
| Segment revenue | Pharmaceuticals ¥2,282.02 thousand (YoY +3.6%), Healthcare business ¥1,253.39 thousand (YoY +5.3%), Global ¥1,160.42 thousand (YoY +29.4%), Real estate leasing ¥97.05 thousand (YoY +5.1%) |
| Segment profit | Pharmaceuticals ¥-704,330 thousand, Healthcare business ¥175,381 thousand, Global ¥154,920 thousand, Real estate leasing ¥39,422 thousand |
| Depreciation and amortization | ¥260,465 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥152,732 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No (no eligible participants) |
| Issued Shares at Period-End | 34,838,325 |
| Treasury Shares at Period-End | 132,499 |
| Factors Behind Changes in Business Performance | Net sales increased due to growth in domestic and overseas sales of “Strong Wakamoto” and an increase in contract manufacturing of ophthalmic products in the global business, among other factors. Gross profit declined due to the impact of the drug price revision and other factors. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to growth in domestic and overseas sales of “Strong Wakamoto” and an increase in contract manufacturing of ophthalmic products in the global business, among other factors. Gross profit declined due to the impact of the drug price revision and other factors, while selling, general and administrative expenses decreased as factors behind the increase in advertising expenses in the same period of the previous year fell away.